The Wall Street Journal @WSJ

Exclusive: An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company’s entire board of directors, ratcheting up pressure on management in a tough environment for biopharmaceutical firms https://t.co/PDJJDjydyQ

www.wsj.com

Exclusive | Avadel Shareholder Seeks Ousting Drugmaker’s Entire Board

ASL Strategic Value Fund wants the narcolepsy drugmaker to retain investment bankers and consider a sale.